Jessica R Allegretti, MD, MPH: Preventing Recurrent C Difficile with CP101

Video

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Jessica R Allegretti, MD, MPH, FACG, Director of Clinical Research, Director, Fecal Microbiota Transplant Program, Associate Director, Crohn's and Colitis Center, Bringham and Women's Hospital, Assistant Professor of Medicine, Harvard Medical School, presented her PRISM3 study at the American College of Gastroenterology 2021 conference.

The study was a double-blind, randomized, placebo-controlled trial that included adults who received standard-of-care for recurrent clostridioides difficile infection (CDI).

Cp101 is an investigational orally administered microbiome therapeutic designed to restore microbiome diversity and enable early intervention in the management of recurrent CDI, according to the study.

Last year at ACG, Allegretti presented data showing that CP101 was significant at preventing recurrent CDI at week 8 post-therapy. This year, Allegretti explained, they looked at microbial diversity.

"It's extremely important in today's age to develop new safe microbiome therapeutics for C diff," Allegretti said.

The next step for CP101 is going to be a large phase 3 study, PRISM4, which should be enrolling later this year.

According to Allegretti, antibiotic stewardship is one of the best tools that clinicians have to fight CDI, which has risen to epidemic levels. CP101 isn't the only CDI treatment in development.

Several companies are working on novel live biotherapeutic products. FMT is effective and safe but it's not viable long-term. Allegretti shared how exciting it is to have multiple treatments in development that are already showing promising results.

"I think it's a really great time to be working in this space," Allegretti said.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.